Aurinia Pharmaceuticals (NASDAQ:AUPH) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP issued its quarterly earnings data on Thursday. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.06, Zacks reports. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. The company had revenue of $59.87 million during the quarter, compared to analysts' expectations of $59.94 million. Aurinia Pharmaceuticals updated its FY 2025 guidance to EPS.

Aurinia Pharmaceuticals Price Performance

AUPH traded up $0.03 during trading on Monday, hitting $7.98. The company's stock had a trading volume of 2,583,066 shares, compared to its average volume of 1,396,134. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -53.20 and a beta of 1.22. The firm's 50 day moving average price is $8.15 and its two-hundred day moving average price is $7.84. Aurinia Pharmaceuticals has a 12 month low of $4.71 and a 12 month high of $10.67.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 19th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.